Try our Advanced Search for more refined results

In Re: Restasis (Cyclosporine Ophthalmic Emulsion) Antitrust Litigation

  1. October 13, 2021

    Allergan Inks $30M Deal With Restasis Buyers In Antitrust Suit

    Allergan has struck a $30 million deal with buyers of dry-eye medication Restasis to end allegations that the pharmaceutical giant fought to keep a generic version of the medication off the shelves.

  2. July 13, 2020

    Restasis Buyers Seek $16M Atty Fees In Antitrust Case

    A class of buyers that reached a $51 million settlement with Allergan over allegations that it illegally kept generic rivals to its dry eye treatment Restasis off the shelves has asked a New York federal judge for more than $16 million in attorney fees and about $2 million in costs.  

  3. May 06, 2020

    Restasis Buyers Win Cert. Battle In Allergan Monopoly Case

    Health care plans, welfare funds and other buyers of Allergan's extremely successful dry eye treatment Restasis have won class certification in the sweeping litigation accusing the drugmaker of illegally keeping generic rivals on the sidelines, with three firms tapped to head up their legal team.

  4. February 26, 2020

    Allergan Inks $51M Deal To End Direct Buyers' Restasis Suit

    Allergan has struck a $51.2 million deal with buyers of dry-eye medication Restasis to end allegations that the pharma giant fought to keep a generic version of the medication off the shelves.

  5. December 05, 2019

    Allergan Says State Laws Doom Restasis Payors' Class Push

    Allergan told a New York federal judge that a group of Restasis buyers can't certify their class claims accusing the pharmaceutical giant of boosting profits by delaying a cheaper generic version of the dry-eye medication, saying some of the state laws from which the claims arise prohibit class actions.

  6. October 11, 2019

    Restasis Payors Defend Class Cert. Bid In Allergan Suit

    A group of Restasis buyers on Friday defended class certification in their New York federal suit accusing Allergan of boosting profits by delaying a cheaper generic version of the dry-eye medication, saying they share numerous, common antitrust injuries.

  7. October 31, 2018

    Allergan, Generic Cos. Battle Over Restasis Launch Plans

    Companies hoping to sell generic versions of Allergan's dry-eye medication Restasis have told a New York federal court overseeing multidistrict antitrust litigation that they'll only provide information about their launch dates to the branded-drug maker's outside counsel, but Allergan insists that its in-house attorneys can be trusted.

  8. September 25, 2018

    Sham Petition Suits Are Piercing Big Pharma's Antitrust Shield

    A long-standing U.S. Supreme Court doctrine shielding companies that petition the U.S. Food and Drug Administration from antitrust liability is proving increasingly unhelpful to brand-name drugmakers accused of delaying generic-drug rivals by bombarding the FDA with cockamamie scientific arguments.

  9. September 19, 2018

    Allergan Loses 'Meritless' Bid To Gut Restasis Antitrust MDL

    A New York federal judge has shot down Allergan Inc.'s "meritless" effort to eviscerate multidistrict litigation that alleges antitrust violations aimed at protecting dry-eye drug Restasis, saying it's plausible that the company acted dishonestly to stymie generic competition.

  10. September 13, 2018

    Allergan Looks To Keep CEO's Tribal Patent Docs Out Of MDL

    Documents from Allergan Inc.'s CEO and general counsel on a deal transferring patents to a Native American tribe are at best "marginally relevant" to multidistrict litigation accusing the company of illegally delaying a generic version of dry-eye medication Restasis, the drugmaker told a New York federal judge Wednesday.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!